This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
the annual number of hospitalisation days, the annual rate of vascular access failure, the average annual use of intravenous iron for in-centre haemodialysis patients, the rate of transplantation, mortality among renal transplant recipients, and utility scores.
Study designs and other criteria for inclusion in the review
A systematic review of the literature was undertaken to identify all relevant studies reporting clinical data. Randomised clinical trials were used, whenever possible.
Sources searched to identify primary studies
MEDLINE and the Cochrane Library were searched, as were abstracts from major nephrology meetings and the authors' personal files.
Criteria used to ensure the validity of primary studies
The validity of the primary studies was ensured by the use of randomised clinical trials.
Methods used to judge relevance and validity, and for extracting data
Not stated.
Number of primary studies included
Nine primary studies provided the evidence.
Methods of combining primary studies
The primary estimates appear to have been combined using narrative methods.
Investigation of differences between primary studies
Results of the review
The annual mortality risk for patients in the reference case was 244.4/1,000.
The annual number of hospitalisation days in the reference case was 13.9 days/patient-years.
The annual rate of vascular access failure in the reference case, adjusted for distribution of access types, was 0.074/hemodyalisis (with arteriovenous fistula at 25%) and 0.216 /haemodialysis (with polytetrafluoroethylene at 75%).
The average annual use of intravenous iron for in-centre haemodialysis patients in the reference case was 1,500 mg/12 months.
The rate of transplantation was 0.054.
The mortality among renal transplant recipients was 0.08 in the first year and 0.038 in the second and subsequent years.
The average utility score for in-centre haemodialysis patients treated to the 11 -12 g/dL haemoglobin level was 0.621.
The utility score for the 9.5 -10.5 g/dL target level was 7.4% lower than the score for the target of 11 -12 g/dL.
The increase in the 12 -12.5 g/dL and 14 g/dL targets were assessed using two different approaches: compared with the 11 -12 g/dL target, the first approach estimated an increase of 0.43% for the 12 -12.5 g/dL target and 1.45% for the 14 g/dL target; and compared with the 11 -12 g/dL target, the second approach produced increases of 3.7% (12 -12.5 g/dL) and 12.3% (14 g/dL), respectively. The average utility score for patients with functioning renal transplant was 0.816.
No survival difference was estimated for patients treated with either of the higher dose EPO strategies.
The rates of hospitalisations were equivalent between the study arms.
The access failure rates were not affected by haemoglobin target.
Measure of benefits used in the economic analysis
The summary benefits measure was the number of quality-adjusted life-years (QALYs) obtained with each treatment strategy. Utility and survival data were derived from the literature. The estimated EPO requirements were also reported. The QALYs were discounted annually at a rate of 3%. The authors stated that there was no evidence that utility scores improve once haemoglobin levels rise above 12.0 g/dL (using physical function scores on the SF-36), but a linear increase was noted for selected dimensions of the HRQOL in certain patients. Therefore, two methods were used to estimate the utilities for the 12 -12.5 g/dL and 14 g/dL targets, as stated already.
Direct costs
Discounting was relevant since the costs were incurred over a long timeframe. An annual rate of 3% was applied. The unit costs were not reported separately from the quantities of resources used. The costs were presented as macrocategories. The health services included in the economic evaluation were EPO and iron treatment, physician services, incentre haemodialysis, hospital stay, outpatient care, and transplantation. Outpatient care comprised the costs of emergency room visits, day surgery, all diagnostic imaging and laboratory tests, and outpatient medications. The cost/resource boundary of the health care purchaser was adopted. Resource use was estimated using data derived from the literature and some assumptions. The costs came from several sources, such as Medicare rates, average wholesale prices, and a published cost study. The price year was 2001.
Statistical analysis of costs
The costs were treated deterministically in the base-case.
Indirect Costs
The indirect costs were not considered in the economic evaluation.
Currency
US dollars ($). The costs were first estimated in Canadian dollars (Can$) and then converted to US dollars. At January 2001 the conversion rate was $1 = Can$1.45.
The use of erythropoietin (EPO) to achieve haemoglobin targets of 11 -12 g/dL led to an incremental cost per qualityadjusted life-years (QALY) gained of approximately $50,000 to $60,000 in haemodialysis patients. However, the objective of reaching haemoglobin levels in excess of 12 g/dL resulted in prohibitive cost-effectiveness ratios (in general, above $500,000 per QALY). The results of the analysis suggested that higher haemoglobin targets did not reduce hospitalisation costs sufficiently to offset the additional costs of EPO.
CRD COMMENTARY -Selection of comparators
The authors provided a justification for the choice of the comparators, which were recommended in different worldwide guidelines for the treatment of haemodialysis patients. You should decide whether they are valid comparators in your own setting.
Validity of estimate of measure of effectiveness
The analysis of effectiveness used results from a systematic review, which was carried out to identify all relevant published studies. Clinical trials were the preferred source, which ensured the validity of the estimates used in the model. Limited information on the methods and conduct of the review was provided. The robustness of the estimates used in the model was tested in a sensitivity analysis, in which nearly all model inputs were investigated.
Validity of estimate of measure of benefit
The summary benefit measure was appropriate as it detected the impact of the interventions on quality of life and survival. It also has the advantage of being comparable with the benefits of other health care interventions. Discounting was applied, as recommended in the USA. The impact of varying the discount rate was examined in the sensitivity analysis. Different methods were used to determine the utility weights.
Validity of estimate of costs

